Eli Lilly Joins FDA Lawsuit Over Compounded Obesity Drugs, Seeks 'Swift End' And 'To Protect Its Interests'
The 15.92% Average Gain in Inauguration Year: Will Trump's Second Term Echo the Trend?
Don't Buy Weight-Loss Medication From Unauthorized Sources, UK Health Agency Warns About Risks
Weight Loss Drugs Can Cut Grocery Spending by up to 9%: Study
Insurance is not covered, supply shortages, rampant generic drugs, slow new drug development, and new weight-loss medications still face challenges.
New GLP-1 weight loss drugs are not only changing the lives of obese populations but also creating billions of dollars in revenue for pharmaceutical companies like Eli Lilly and Co and Novo-Nordisk A/S. However, analysis indicates that weight loss drugs currently face some challenges in the USA: there is the risk of insurance companies refusing to pay, and ongoing supply shortages have created opportunities for lower-priced generic drugs. Additionally, it remains uncertain whether pharmaceutical companies can truly develop better weight loss medications and what the new U.S. government's attitude toward weight loss drugs will be.
Jefferies Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $994
